HereS a breakdown of the key takeaways from the provided text, focusing on the FDA’s new guidance documents:
1. Wellness Device Regulations – More Leeway for Wearables
* Looser Rules: The FDA is clarifying what qualifies as a “wellness device,” offering more flexibility for wearables that track metrics like heart rate, blood pressure, and blood glucose if they are solely for wellness purposes.
* Blood Pressure Example: A wearable tracking sleep, pulse, and blood pressure with validated blood pressure readings would be considered a wellness device.
* Whoop Case: This guidance seems to address the previous warning letter sent to Whoop regarding it’s blood pressure feature. Whoop welcomes the clarification.
* Glucose Monitoring Caveat: Wearables estimating blood glucose for nutritional monitoring are okay, unless they use microneedle technology.the FDA continues to warn against non-invasive blood glucose claims (smartwatches/rings).
* Consistency: The FDA acknowledges past inconsistencies in regulating wellness features (e.g., allowing pulse rate but not other measurements).
2. Clinical Decision Support Software – Reduced Regulation
* Key Change: Software providing a single medical recommendation is now exempt from FDA regulation. Previously, such software would have been classified as a medical device.
* Risk assessment Example: Software predicting long-term cardiovascular risk based on common factors (weight,smoking,blood pressure) is exempt.
* Higher Risk Scenarios: Software predicting risk within 24 hours or using genomic data would be considered a medical device and subject to regulation.
Overall Impact:
* Innovation: The FDA aims to “promote more innovation with AI in medical devices” through these changes.
* Clarity: The guidance seeks to provide clearer boundaries between wellness insights and medical diagnosis/treatment,reducing uncertainty for companies.
* Industry Response: Companies like Whoop and Oura (working on blood pressure features) have welcomed the changes.
Related reading